Stacie S. Aarestad

Partner, Co-Chair, Capital Markets Practice - Boston

Stacie Aarestad
Download Media Photo

Contact Information

617.832.1108

617.832.7000

saarestad@foleyhoag.com Download vCard

Stacie Aarestad is a partner at Foley Hoag and Co-Chair of the firm's Capital Markets Practice. She focuses on corporate and securities law matters, public company representation and merger and acquisition transactions. Stacie represents issuers in a broad range of capital market transactions, including public and private offerings of debt and equity securities, and also advises companies with respect to tender offers, exchange offers, debt repurchases and stock buybacks.

More »

Education:

  • Boston University School of Law, J.D., magna cum laude, 1997
  • Colgate University, B.A., magna cum laude, Phi Beta Kappa, 1991

Languages:

English

Representative Experience

  • Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a multi-state cannabis operator
    • in closing an underwritten public offering worth of approximately US$228 million of subordinate voting shares
    • in its C$115.5 million offering of subordinate voting shares
  • Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases in a number of capital markets transactions, including:
    • an “at the market offering” program having an aggregate offering price of up to $50 million, with Cantor Fitzgerald & Co.
    • its underwritten public offering of 16,741,573 shares of its common stock, together with accompanying warrants to purchase 8,370,786 shares of common stock for gross proceeds of approximately $74.5 million
    • its sales agreement with Cantor Fitzgerald & Co. for an up to $25 million ATM offering
    • its $37.4 million underwritten public offering of common stock
  • Organogenesis Holdings Inc. (Nasdaq: ORGO) in multiple capital markets transactions, including
    • $64.7 million underwritten public offering of Class A common stock
    • $50.3 million underwritten public offering of Class A common stock
    • in its warrant exchange offer and consent solicitation
    • a SPAC IPO/reverse merger of Organogenesis Inc. with and into a wholly owned subsidiary of Avista Healthcare Public Acquisition Corp. (AHPAC), with Organogenesis Inc. surviving the merger and AHPAC changing its name to Organogenesis Holdings Inc.
  • Sensata Technologies, Inc., an indirect, wholly owned subsidiary of Sensata Technologies Holding plc (NYSE: ST), in its Rule 144A offering of $450 million in aggregate principal amount of 4.375% senior notes due 2030
  • Good Start Genetics in a merger with genetic information company Invitae Corporation (NYSE: NVTA)
  • Enanta Pharmaceuticals, Inc. (Nasdaq: ENTA) in its initial public offering of common stock 
  • Zosano Pharma Corporation (Nasdaq: ZSAN):
    • $50.0 million underwritten public offering of common stock
    • $29.3 million underwritten public offering of common stock
    • $7.5 million PIPE of units (common stock and warrants) with warrants exercisable for an additional $14.4 million
  • Dyax Corp. (Nasdaq: DYAX) in its sale to Shire plc.
  • Dyax Corp. in public securities offerings including:
    • $230,000,000 underwritten public offering of common stock
    • $80,000,000 underwritten public offering of common stock
    • $65,000,000 underwritten public offering of common stock
    • $30,000,000 registered direct offering of common stock
    • $63,537,500 underwritten public offering of common stock
    • $21,000,000 underwritten public offering of common stock
    • $17,250,000 underwritten public offering of common stock
    • $50,000,000 Committed Equity Financing Facility with Azimuth Opportunity Ltd.
    • $44,300,000 underwritten public offering of common stock
  • Dyax Corp. in connection with secured loans including:
    • $65,000,000 loan agreement with Cowen Healthcare Royalty Partners, L.P., consisting of a $50,000,000 Tranche A loan and a $15,000,000 Tranche B loan, secured by Dyax’s phage display Licensing and Funded Research Program
    • $30,000,000 royalty interest assignment agreement with Paul Capital Partners
  • Bolt Technology Corporation (Nasdaq: BOLT) in its sale to Teledyne Technologies Incorporated (NYSE: TDY)
  • NewStar Financial, Inc. (Nasdaq: NEWS) in securities offerings:
    • $300,000,000 144A offering of 7.25% Senior Notes due 2020
    • $125,000,000 PIPE with institutional investors including, Corsair Capital, Union Square Partners and Och-Ziff Capital Management, Swiss Re and SAB Capital
  • Lamar Advertising Company (Nasdaq: LAMR) in its REIT conversion
  • Lamar Advertising Company and its wholly owned subsidiary Lamar Media Corp. in high yield and convertible debt offerings and tender offers including:
    • $400,000,000 144A offering of 5 3/4% Senior Notes due 2026
    • $510,000,000 144A offering of 5 ⅜% Senior Notes due 2024 with follow-on exchange offer
    • $535,000,000 144A offering of 5% Senior Subordinated Notes due 2023 with follow-on exchange offer
    • $500,000,000 144A offering of 5 ⅞% Senior Subordinated Notes due 2022 with follow-on exchange offer
    • $400,000,000 144A offering of 7 ⅞% Senior Subordinated Notes due 2018 with follow-on exchange offer
    • Cash Tender Offer and Consent Solicitation for all of Lamar’s then outstanding 7 ¼% Senior Subordinated Notes due 2013
    • Tender Offer to eligible employees and directors to exchange certain outstanding options to purchase the Company's Class A common stock for a lesser number of new options
    • Cash Tender Offers for all of Lamar’s then outstanding 2 ⅞% Convertible Notes due 2010—Series B
    • $350,000,000 144A offering of 9 ¾% Senior Notes due 2014 with follow-on exchange offer
    • $275,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series C with follow-on exchange offer
    • Exchange Offer of a new series of 2 ⅞% Convertible Notes due 2010—Series B for all outstanding 2 ⅞% Convertible Notes due 2010
    • $216,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series B with follow-on exchange offer
    • $400,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015 with follow-on exchange offer

Honors

  • "Top Women of Law," Massachusetts Lawyers Weekly, 2014
  • Selected for the Greater Boston Chamber of Commerce’s Executive Leadership Institute, 2014
  • Articles Editor, Boston University Law Review
  • Albert P. Pettoruto Memorial Award

Involvement

  • Member, American Bar Association
  • Member, Massachusetts Bar Association
  • Member, Boston Bar Association
  • Member, Board of Directors, Massachusetts Biotechnology Education Foundation, Inc. (MassBioEd)
  • “Multitrack Exit Strategies: M&A, IPO, Direct Listing, SPAC, or All of the Above?” – Boston Bar Association: 2021 Corporate Deals Conference (April 2021) 
  • “SPACs: A Fad or Here to Stay?” - Foley Hoag M&A Forum (February 2021)
  • “Sponsors, Influencers & Career Engineering” – Centerforce: Women, Diversity & Change Conference (April 2019)
  • “Corporate Social Responsibility: Emerging Expectations for Public Companies” – Foley Hoag Webinar (May 2018)
  • “Planning for Exit: Top 5 Pitfalls” – MassTLC: Boston New Co  (April 2018)
  • “Getting Capital, Going Public, Going Global” - Kendall Square Association: Third Thursday (April 2014)
 
Add to Bio Folder

Download Bio

Bar Admissions

  • Massachusetts